. Therefore, the quantitadrug, by microvascular aromatic amino acid decarboxyltively important barrier system within the brain is the ase (AAAD). BBB at the capillary endothelium ( Figure 1A) . Despite Active Efflux Barrier. Certain drugs may cross the enthe vast surface area of the human BBB, the thickness dothelial barrier via free diffusion and undergo influx from the blood to the brain compartment. However, this influx can be immediately followed by active efflux from
Drug Lipidization. The BBB permeability-surface area nant proteins do not cross the BBB in pharmacologically significant amounts. Consequently, virtually all current (PS) product is an experimental measure of BBB permeability to a given drug. The BBB PS product for small neurotrophin CNS drug development programs are focused on the discovery of small molecule peptidomimetmolecules may be increased with lipidization via either (1) the reduction in hydrogen bonding of the drug ics. However, most small molecule peptidomimetics will not have molecular characteristics that pass the strinthrough conjugation of lipid-soluble functional groups to water-soluble moieties on the drug, or (2) conjugation gent criteria discussed above for effective BBB transport. Therefore, the small molecule peptidomimetic of the drug to a lipid carrier such as free fatty acid, adamantane, or dihyropyridine. A problem with drug would benefit from reformulation with a BBB drug delivery strategy to be pharmacologically active in the brain. lipidization is that the uptake of the lipidized drug by peripheral organs is also increased, and this causes The development of a small molecule drug that crosses the BBB can be just as difficult as the development of a reduction in the plasma concentration of the drug. Therefore, the increased BBB transport caused by lipidia large molecule drug that is transported across the BBB. Therefore, one alternative is to reformulate the zation is offset by the increased uptake of the drug by peripheral tissues (Pardridge, 2001) . large molecule drug with a BBB drug delivery strategy. This has been done with the chimeric peptide technolProtein Cationization. The cellular uptake of proteins may be increased by cationizing the protein, which trigogy, wherein a nontransportable peptide is conjugated to a BBB transport vector, which functions as a molecugers electrostatic interactions with anionic groups on
